ArticleJournal of general internal medicine2026
COVID-19 Vaccination and Kidney Disease : SARS-CoV-2 Vaccine Effect on Risk of Infection and Subsequent Outcomes in Patients with Chronic Kidney Disease.
Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBenefit of SARS-CoV-2 vaccinations to reduce the risk of infection and subsequent outcomes in patients with impaired kidney function beyond end-stage kidney disease (ESKD) remains uncertain.
objectivesTo evaluate the vaccination effect on rates of SARS-CoV-2 infection and subsequent risk of 30-day mortality outcomes in patients with kidney disease.
methodsPopulation-based retrospective cohort on nationwide data from multiple national health care registers between February 2021 and June 2022. All vaccine uptake and efficacy were evaluated in granular eGFR categories with comparison of age- and gender-standardized rates of SARS-CoV-2 infection and subsequent risks of 30-day mortality between unvaccinated, vaccinated, and booster-vaccinated persons.
resultsBased on a population of 982,047 adults with kidney disease, a total of 359,428 SARS-CoV-2 infections (Alpha: n = 7861, Delta: n = 27,868, Omicron: n = 323,699) were identified. Vaccination and booster vaccination were associated with benefits on rates of SARS-CoV-2 infection and subsequent 30-day mortality, with age- and gender-standardized rate ratios for SARS-CoV-2 infection of 0.24 (95% CI 0.21-0.28), 0.33 (95% CI 0.22-0.50), 0.32 (95% CI 0.19-0.54), 0.91 (95% CI 0.32-2.58), and 0.24 (95% CI 0.08-0.73) and age- and gender-standardized 30-day mortality differences of -1.5 (95% CI -1.7, -1.2), -5.8 (95% CI -7.1, -4.5), -12.4 (95% CI -15.3, -9.5), -16.9 (95% CI -21.9, -11.8), and -10.7 (95% CI -16.6, -4.8) for booster vaccinations compared with no vaccination for eGFR ≥ 60 mL/min/1.73 m
conclusionsVaccination and booster vaccination against SARS-CoV-2 were associated with benefits on rates of SARS-CoV-2 infections and associated 30-day mortality risk irrespective of kidney function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.